Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Portfolio News / By Karina Tin November 25, 2024 Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Read More »
Remix Therapeutics™ to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH) Portfolio News / By Karina Tin November 20, 2024 Remix Therapeutics™ to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH) Read More »
Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer Portfolio News / By Karina Tin November 20, 2024 Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer Read More »
Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024 Portfolio News / By Karina Tin November 15, 2024 Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024 Read More »
Kenai Therapeutics Establishes Patient Advisory Board Portfolio News / By Karina Tin November 14, 2024 Kenai Therapeutics Establishes Patient Advisory Board Read More »
RAPT Therapeutics Reports Third Quarter 2024 Financial Results Portfolio News / By Karina Tin November 12, 2024 RAPT Therapeutics Reports Third Quarter 2024 Financial Results Read More »
ORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates Portfolio News / By Karina Tin November 12, 2024 ORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates Read More »
RAPT Therapeutics Stops Zelnecirnon Program Based on Recent FDA Feedback Following Clinical Hold Due to Single SAE of Severe Liver Injury Portfolio News / By Karina Tin November 11, 2024 RAPT Therapeutics Stops Zelnecirnon Program Based on Recent FDA Feedback Following Clinical Hold Due to Single SAE of Severe Liver Injury Read More »
A2 Bio Highlights Progress of Tmod TM CAR T-Cell Clinical Programs during 2024 Annual Meeting of the Society for Immunotherapy of Cancer Portfolio News / By Karina Tin November 9, 2024 A2 Bio Highlights Progress of Tmod TM CAR T-Cell Clinical Programs during 2024 Annual Meeting of the Society for Immunotherapy of Cancer Read More »
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Portfolio News / By Karina Tin November 6, 2024 Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Read More »
